Innovent

Closeup of blue eye on black background
Biotech

Innovent eyes China approval after matching Eylea in phase 3

Innovent’s prospect matched Bayer and Regeneron’s Eylea, teeing up filings for Chinese approval of a molecule that could cut maintenance dosing.
Nick Paul Taylor Mar 24, 2026 6:00am
Takeda

Takeda inks $1.7B AI discovery deal with Iambic Therapeutics

Feb 9, 2026 8:00am
A ballpoint pen rests on top of a stack of documents ready for signing

Lilly, Innovent pen $8.8B collab 'beyond traditional licensing'

Feb 9, 2026 6:45am
gold coins and bars

Takeda strikes Innovent pact worth up to $11.4B

Oct 22, 2025 9:15am
blocks stack target climb build arrow meet

Awaiting regulator verdict, Innovent posts latest psoriasis win

Oct 29, 2024 9:50am
Graphic image of an arrow nailing the bullseye of a target

Innovent bags another phase 3 win for next-gen Lilly GLP-1 drug

Jul 22, 2024 5:31am